Percutaneous aoric valve implantaion (TAVI) is well established treatment opion for high risp paients with severe aoric stenosis. Transcatheter aoric valve implantaion (TAVI) is an atracive treatment opion for paients with failing bioprostheses (valve-in-valve concept), especially in elderly paients with high risk for reoperaion. Although clinical experience is sill limited for this of-label indicaion, the procedure has been shown to be feasible in stented as well as stentless bioprostheses. We report a case of of 71-years old woman were CoreValve 23 mm (Medtronic, Inc., Minneapolis, Minnesota, USA) was implanted inside a degenerated Sorin Freedom SOLO bioprosthesis using transfemoral approach. Freedom SOLO bioprosthesis stentless bioprosthesis is sutured in supra-annular posiion and presents a TAVI challenge due to its proximity to coronary osia. Careful pre-procedural planning with TEE and CTA is crucial. We decided for transfemoral approach with 23 m CoreValve implantaion. Balloon valvuloplasty before TAVI with contrast injecion may predict the inal result and is helpful for procedure success and risk reducion. The inal TAVR result was good. This case proves the ViV concept for stentless Freedom SOLO bioprosthesis.
Background
T he most efecive treatment for paients with severe symptomaic aoric stenosis is surgical replacement of the valve. 1 Aortic valve replacement with a bioprosthesis is preferred, especially in older populaions, due to its saisfactory hemodynamic performance without warfarin related complicaions. Sorin Freedom SOLO bioprosthesis (Sorin Biomedica Cardio, Saluggia, Italy) is implantated in the supra-annular posiion. According to available data the SOLO valve is durable with good hemodynamic performance and low complicaion rates. [2] [3] [4] In our insituion more than 500 implantations were performed in the last 8 years. 5 It should not be unexpected that a considerable number of paients may require reintervenion due to a dysfuncional bioprosthesis with structural valve deterioraion. Surgical treatment of degenerated aoric bioprostheses is associated with an increased risk of morbidity and mortality, especially in elderly paients with signiicant co-morbidities. Therefore, transcatheter aortic valve implantaion (TAVI) performed as valve in valve (VIV) technique appears as an attractive alternative treatment option. [6] [7] [8] [9] Pericardial stentless aortic biopro-sthesis Freedom Solo represents a challenge for VIV implantaion due to its supra-annular posiion potenially leading to coronary obstrucion.
We report a case of ViV implantaion by transfemoral approach with a 23-mm self-expandable prosthesis Core-Valve (Medtronic, Inc., Minneapolis, Minnesota, USA) inside a degenerated Sorin Freedom SOLO bioprosthesis.
Case presentaion (Core Valve in Freedom Solo valve)
71-years old woman underwent surgical aoric valve replacement with a 25-mm Freedom Solo bioprosthesis in 2007. During the same surgical procedure bypass grat with let internal mammary artery (LIMA) let to LAD and venous grats to the irst (OM1) and second (OM2) obtuse marginal coronary artery was also done. Five years ater the surgery she presented to our insituion with dispnea (New York Heart Associaion funcional class II to III). Echocardiographic examinaion revealed degeneraion of the aoric bioprosthesis (mean gradient across the aortic valve of 28 mmHg and aortic valve area of 0.83 cm 2 ). She refused any other further evaluaion and tre-Srce i krvni sudovi 2014; 33(1): 27-29 atment and was discharged. She presented again ater one year with severe heart failure. An echocardiogram revealed a progression of the biologic aoric valve degeneraion with severe aoric stenosis (mean gradient of 50 mmHg, aoric valve area of 0.6 cm 2 ) and mild to moderate aoric regurgitaion. The global systolic funcion of the let ventricle was preserved with the ejecion fracion of 65%. A severe pulmonary hypertension of 85 mmHg was also found. Cardiac catheterizaion showed patent coronary artery bypasses with no new signiicant disease on other coronary arteries. Due to several comorbidities (chronic obstrucive pulmonary disease with severe obstrucive and restricive respiratory failure, chronic renal disease, diabetes on insulin, severe obesity, previous cardiac surgery) the surgical risk was high (logisic Euroscore of 31%) and she was refused for aoric valve re-replacement. TAVI was considered and shown to be feasible after morphological evaluaion with mulidetector computed tomography and transesophageal echocardiography.
One week after the admission we performed the percutaneus procedure under general anestesia. First we inserted a SPIDER Embolic Protecion Device in the right internal caroid artery to prevent embolic events. Then balloon aortic valvuloplasty with aortic angiography was done for the final valvular sizing and to explore the anatomical relaion of the opened surgical prosthesis lealets to the coronary osia (Figure 1 B) . After the vuloplasty a 23-mm self-expandable CoreValve (Medtronic, Inc., Minneapolis, Minnesota, USA) was implanted via femoral access (Figure 1 C) . The transcatheter prosthesis was expanded during rapid pacing under luoroscopic and transesophageal guidance. The inal angiographic result was excellent, showing good opening of the trancatheter valve lealets and fully patent coronary osia (Figure 3 D) . Echocardiogram ater implantaion showed good hemodynamic properies of the transcatheter valve with a maximal gradient of 20 mmHg, esimated aoric valve area of 1.7 cm 2 and mild paravalvular regurgitaion (Figure 2 ).
Discussion
Increased life expectancy and improvement in clinical outcome following surgery has led to an increasing number of elderly paients with a history of prior aoric valve replacement (AVR). As a consequence, a considerable number of paients may require reintervenion due to a dysfuncional bioprosthesis with structural valve deterioraion. Transcatheter aoric valve implantaion (TAVI) has become an established surgical alternaive in paients with aoric stenosis and severe comorbidiies. Freedom Solo aoric valve is stentless bioprosthesis that is implanted in a supravalvular posiion, which is paricularly beneicial in elderly paients with severely calciied aoric valves rendering diicult the convenional implantaion in the annular posiion. 2, 3, 5 During valve-in-valve implantaion supra-annular bioprostheic posiion presents a technical challenge since bioprostheic lealets may extent to aoric wall and potenially obstruct coronary osia. Careful pre-procedural planning with multidetector computed tomography and three-dimensional transesophageal echocardiography is important for the assessment of aoric root anatomy, relaionship of the bioprostheic lealet height in relaion to coronary osia and size of the prosthesis oriice. 10, 11 In addiion, balloon valvuloplasty before TAVI is useful for checking the posiion of the opened bioprostheic lealets in relaion to coronary osia and for inal valvular sizing.
In the reported case we have shown that valve-in-valve procedure for failing supra-annular bioprosthesis Freedom Solo is feasibile, considering technical diiculies.
